115 related articles for article (PubMed ID: 10644933)
1. First-line chemotherapy with vinorelbine and paclitaxel as simultaneous infusion in advanced breast cancer.
Vici P; Amodio A; Di Lauro L; Conti F; Gionfra T; Belli F; Lopez M
Oncology; 2000; 58(1):3-7. PubMed ID: 10644933
[TBL] [Abstract][Full Text] [Related]
2. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
[TBL] [Abstract][Full Text] [Related]
3. Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicin-treated patients.
Ellis GK; Gralow JR; Pierce HI; Williams MA; Livingston RB
J Clin Oncol; 1999 May; 17(5):1407-12. PubMed ID: 10334525
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure.
Martín M; Lluch A; Casado A; Garciía Carbonero I; de Paz L; Esteban C; Insa A; Alfonso R; García-Conde J; Diaz-Rubio E
Ann Oncol; 2000 Jan; 11(1):85-9. PubMed ID: 10690393
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients.
Michelotti A; Gennari A; Salvadori B; Giannessi PG; Baldini E; Tibaldi C; Da Prato M; Conte PF
Semin Oncol; 1996 Oct; 23(5 Suppl 11):38-40. PubMed ID: 8893898
[TBL] [Abstract][Full Text] [Related]
6. Full dose paclitaxel plus vinorelbine as salvage chemotherapy in anthracycline-resistant advanced breast cancer: a phase II study.
Polyzos A; Tsavaris N; Kosmas C; Gogas H; Toufexi H; Kosmidis C; Markopoulos C; Giannopoulos A; Papadopoulos O; Stamatiadis D; Kouraklis G
J Chemother; 2003 Dec; 15(6):607-12. PubMed ID: 14998089
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma.
Ibrahim NK; Buzdar AU; Valero V; Dhingra K; Willey J; Hortobagyi GN
Cancer; 2001 Feb; 91(4):664-71. PubMed ID: 11241232
[TBL] [Abstract][Full Text] [Related]
8. Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor.
Kornek GV; Haider K; Kwasny W; Hejna M; Raderer M; Meghdadi S; Burger D; Schneeweiss B; Depisch D; Scheithauer W
Br J Cancer; 1996 Nov; 74(10):1668-73. PubMed ID: 8932353
[TBL] [Abstract][Full Text] [Related]
9. Vinorelbine combined with paclitaxel infused over 96 hours (VI-TA-96) for patients with metastatic breast carcinoma.
Cocconi G; Mambrini A; Quarta M; Vasini G; Bella MA; Ferrozzi F; Beretta MD
Cancer; 2000 Jun; 88(12):2731-8. PubMed ID: 10870055
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
11. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.
Livingston RB; Ellis GK; Gralow JR; Williams MA; White R; McGuirt C; Adamkiewicz BB; Long CA
J Clin Oncol; 1997 Apr; 15(4):1395-400. PubMed ID: 9193331
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor.
Kornek GV; Ulrich-Pur H; Penz M; Haider K; Kwasny W; Depisch D; Kovats E; Lang F; Schneeweiss B; Scheithauer W
J Clin Oncol; 2001 Feb; 19(3):621-7. PubMed ID: 11157011
[TBL] [Abstract][Full Text] [Related]
13. [Simultaneous infusion of vinorelbin and taxol as first-line chemotherapy in metastasized breast cancer].
Vici P; Conti F; Amodio A; Belli F; Della Giulia M; Mariotti S; Gionfra T; Lopez M
Clin Ter; 1998; 149(4):255-9. PubMed ID: 9866885
[TBL] [Abstract][Full Text] [Related]
14. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma.
Ibrahim NK; Rahman Z; Valero V; Willey J; Theriault RL; Buzdar AU; Murray JL; Bast R; Hortobagyi GN
Cancer; 1999 Oct; 86(7):1251-7. PubMed ID: 10506711
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer.
Ibrahim NK; Rahman Z; Valero V; Murray JL; Frye D; Hortobagyi GN
Cancer Invest; 2002; 20(1):29-37. PubMed ID: 11852999
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
Schwartsmann G; Mans DR; Menke CH; Xavier N; Caleffi M; Ferreira Filho AF; Schunemann H; Kalakun L; Koya R; Pohlman P; Venegas LF
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):24-9. PubMed ID: 9144687
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: a phase II study.
Michelotti A; Gennari A; Salvadori B; Tognoni A; Tibaldi C; Baldini E; Conte PF
Ann Oncol; 1996 Oct; 7(8):857-60. PubMed ID: 8922202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
